Key words: Centromere protein B (CENP-B)/antigenic determinant/anticentromere antibodies/epitope mapping /mammalian cells ABSTRACT. Centromere protein B (CENP-B) is one of the centromere DNAbinding proteins constituting centromere heterochromatin throughout the cell cycles. Somecomponents of mammaliancentromeres including CENP-Bare target antigens for autoimmune disease patients, often those with scleroderma. Recent isolations of CENP-Bgenes from humanand mouse suggested that CENP-Bwas highly conserved among mammals. From the previous analysis of the reactivity of patient anticentromere sera, two autoepitopes have been located on the DNAbinding domain at the amino-terminal region. The amino acid sequences for both the epitopes are perfectly conserved in the two species, human and mouse. In this study, to identify a human-specific antigenic determinant, the remaining two epitopes were further located in separate carboxyl-terminal regions of humanCENP-B.Although the amino acid sequence of one epitope is identical to that of the corresponding region in mouse CENP-B,the other has a less homologous sequence. To confirm that the latter epitope was available for production of human-specific anticentromere antibodies, mice were immunizedwith the recombinant human CENP-Bproduct. One serum that exclusively stained human centromere structure, but not that of other mammals,was identified in the immunofluorescence microscopic observation. The epitope analysis showed that the less conserved one was recognized by this serum. These results suggested that the corresponding region defines the antigenic determinants for the species specificity.
ABSTRACT. Centromere protein B (CENP-B) is one of the centromere DNAbinding proteins constituting centromere heterochromatin throughout the cell cycles. Somecomponents of mammaliancentromeres including CENP-Bare target antigens for autoimmune disease patients, often those with scleroderma. Recent isolations of CENP-Bgenes from humanand mouse suggested that CENP-Bwas highly conserved among mammals. From the previous analysis of the reactivity of patient anticentromere sera, two autoepitopes have been located on the DNAbinding domain at the amino-terminal region. The amino acid sequences for both the epitopes are perfectly conserved in the two species, human and mouse. In this study, to identify a human-specific antigenic determinant, the remaining two epitopes were further located in separate carboxyl-terminal regions of humanCENP-B.Although the amino acid sequence of one epitope is identical to that of the corresponding region in mouse CENP-B,the other has a less homologous sequence. To confirm that the latter epitope was available for production of human-specific anticentromere antibodies, mice were immunizedwith the recombinant human CENP-Bproduct. One serum that exclusively stained human centromere structure, but not that of other mammals,was identified in the immunofluorescence microscopic observation. The epitope analysis showed that the less conserved one was recognized by this serum. These results suggested that the corresponding region defines the antigenic determinants for the species specificity.
In connective tissue diseases, autoantibodies have been shown to be highly specific in the reaction with intracellular components of cells (see ref. 26 for a review). Somecomponentsof humancentromere structure are also recognized as the target antigens in autoimmune disease patients whooften suffer from scleroderma, as originally reported by Moroi et al. (16) . So far, three centromere antigens have been consistently identified as human centromere proteins (CENPs); 17 kDa (CENP-A), 80kDa (CENP-B) and 140kDa (CENP-C) by the groups of Earnshaw and Rothfield (7), del Mazo et al.
(10) and Muro et al. (18) . Crossreactivity of affinityeluted anticentromere antibodies suggested that these three antigens shared someantigenic determinants, although the precise epitope of each antigen remains unknown(7). In addition, manyother mammaliancentromeres such as hamster, mouse (16, 17) , rat, muntjac, rat kangaroo (4), porcine, rabbit (13), and bovine (20) are also immunoreactive to the patient sera as well, suggesting the existence of another commonantigenic determi- Abbreviations: CENPs, centromere proteins; CENP-B, centromere protein B; IPTG, isopropyl-/3-D(-)-thiogalactopyranoside.
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nant amongmammals.To clarify each centromere antigenic determinant, however, it is essential to obtain monospecific anticentromere antibodies that react only with a defined antigen, since these patient sera often contain polyclonal anticentromere antibodies which recognize two or more centromere antigen molecules (7, 18) . Besides, the epitope analysis might help us to assign some domain structures to humanCENP-B,since it has been demonstrated that autoepitopes are often localized on active sites or functioning regions (26) . Wehave recently isolated a human CENP-BCDNA and succeeded in expressing its gene product functionally in Escherichia coli (24) . The biochemical analyses of human CENP-Bdemonstrated that it has specific DNA binding activity to a 17 bp motif on some families of human centromeric alphoid DNArepeats (14, 15, 24, Muro, Y. etal.9 J. CellBioL 116: 585) . The DNAbinding domain has been precisely located within the N-terminal 134 amino acid residues, in which a helix-loop-helix structure could be predicted as in the case of some other DNAbinding proteins (24, 25) . Recently, a mouse homologue for CENP-B gene has been isolated by Sullivan and Glass (25) , and the predicted amino acid se-quence corresponding to the DNAbinding domain has been shown to be perfectly conserved. Therefore, CENP-Bwas considered to be a centromere DNAbinding protein commonin mammals,sharing the common antigenic determinants for anticentromere patient sera. In this study, to understand the organization of the antigenic determinants of CENP-Band to find a human-specific antigenic determinant, four autoepitopes are characterized on the recombinant human CENP-B polypeptides using a variety of anticentromere sera from autoimmune disease patients (18, 19) . In addition to two epitopes located on the amino-terminal half of the DNAbinding domain (24) , the other two are located on the separate carboxyl-terminal regions with unknownfunction. Weshow that only one epitope has a less homologous sequence and is available for production of an antiserum specific to humancentromere structure, not that of other mammals.
MATERIALS AND METHODS
Sera. Patient anticentromere sera were previously described (18, 19) . To obtain a mouse anti-CENP-B serum, a recombinant human CENP-Bwas expressed in Escherichia coli (E. coli) strain Yl-1 1 which had been constructed by lysogenizing the original recombinant lambda clone (il-l l), in which was inserted the 2.8 kb CDNAencoding the whole CENP-B region except the initiation codon (23, 24) . Yl-ll cells were grown in LB mediumand the expression of the fused CENP-B products was induced in the presence of isopropyl-/3-D(-)-thiogalactopyronoside (IPTG), as described elsewhere (1 1). Induced cells were solubilized in an SDSsample buffer and subjected to electrophoresis on 7.5% or 10% SDS-polyacrylamide gels. The detailed procedure for production of a mouse anti-CENP-B serum and a rabbit serum against T7 phage gene 10 product using the protein bands separated in the gel has been described elsewhere (1).  pCENPBl-1 , and pCENPB2-6, has been constructed by deleting the original plasmid pCENPBl-1 1 stepwisely from the Cterminal Notl site (see Fig. 3a in ref. 24) . The coding region of each construct described below was schematically represented in the text figure (see Fig. 1 were constructed by ligating the oligonucleotides encoding the amino acid residues between 535 and 553, namely,
with the longer EcoRl-Ncol fragments of pCENPB2-6, pCENPBl-1 and pCENPB2-16, respectively.
The gene manipulation was followed by the standard procedures (21) .
Immunoblotting. Truncated recombinant CENP-B products were expressed in E. coli BL21 (DE3) strain harboring each plasmid construct, as described (22) . Immunoblotting procedures were previously described (18), except that the transfer of proteins to PVDFmembrane(Millipore) was done using the Trans-blot SD (Bio-Rad) according to their instructions. The membrane wasincubated with anticentromere sera, which were then visualized with horseradish peroxidase-conjugated second antibodies (Bio-Rad) as described (12), or using ECLwestern blotting detection reagents (Amersham International pic).
RESULTS
Analysis of autoepitopes on human CENP-B, Human centromere protein B (CENP-B) is a centromere DNAbinding protein that has specific DNAbinding activity to a 17 bp motif on certain families of human cen-tromeric alphoid DNArepeats (14, 15, 24, Muro, Y. et al.9 in press). The DNAbinding domain has been finely located on the N-terminal 134 amino acid residues which possessed the predicted helix-loop-helix structure on the N-terminal half and a leucine zipper-like motif on the C-terminal half (24) . Using a number of anticentromere autoimmune sera (18, 19) , at least four autoepitopes from I to IV have been predicted on the human CENP-B by the previus preliminary epitope analysis (see Fig. 1 top) . However, the precise location of epitopes I and II remained unknown,since we used truncated CENPBproducts which had been deleted exclusively from the C-terminus.
To characterize the latter two epitopes further, we here prepared another set of CENP-B constructs as shown in Fig. 1 . We used a plasmid pCENPBl as the parental plasmid, since both epitopes were anticipated to exist within this region. To dissect the two epitopes independently, we first divided this region into two portions at the Ncol site at position 548. The N-terminal part between positions 438 and 548 was retained in the plasmid pCENPBl/N and the remaining C-terminal part was retained in the plasmid PCENPB/NL. The truncated CENP-Bproducts were expressed in Escherichia coli as a fusion protein to T7 phage gene 10 product under control of IPTG-inducible T7 RNApolymerase (22) .
To examine whether the antigenicity was still retained within the separate regions, we tested the reactivity of a variety of anticentromere patient sera by immunoblotting procedure (18) . As expected, the CENP-Bproduct encoded in the parental plasmid pCENPBlwas immunoreactive to all the patients (Fig. 2 , lane 1 in all panels). After the dissection of this region, the N-terminal portion encoded in the pCENPBl/Ncorresponding to epitope II, was indeed recognized by some patient sera ( This result indicated that the C-terminal antigenic determinant, probably for epitope I, was destroyed by the dissection at the Ncol site and that epitope II was located within the region between position 438 and 548. The C-terminal boundary of epitope II was mapped using two additional plasmid constructs, pCENPBl/1-12 and pCENPBl/A. As shown in lane 4 in panels b9 d, Wethen limited the antigenic determinant for epitope I. The absence of the antigenicity in the polypeptide encoded in the PCENPB/NLsuggested that its antigenic determinant was extended further upstream of the Ncol site at position 548 (see Fig. 1 ). However, we could not find any suitable restriction site that could be used to supplement the lost upstream region on a plasmid construction. Instead, we synthesized the oligonucleotides covering the upstream CENP-Bregion between 535 and 553 (see Materials and Methods for details). In this way, the plasmid, PCENPBO/2-6 was obtained by inserting the DNAfragment at the Ncol site at position 553. In a similar immunoblotting analysis shown in Fig.   3 , the truncated CENP-Bproduct now became immunoreactive to all the patients. Therefore, the N-terminal boundary of epitope I was determined at position 535. Similarly, the C-terminal boundary was examined using two additional constructs, PCENPBO/1-1 and PCENPBO/2-16. However, antigenicity was no longer detected in the polypeptides encoded by these constructs (lanes 1 and 2 in Fig. 3 ). From these results, we concluded that the antigenic determinant for epitope I was within the C-terminal 65 amino acid residues between positions 535 and 599.
Grouping of anticentromere positive patient sera. The four epitopes have been finely located on the recombinant humanCENP-B.According to the reactivity to each epitope, the forty anticentromere patient sera were nowgrouped into six categories, combining the reactivity to epitopes III and IV (lanes 7 and 8 in all panels, The truncated CENP-Bproducts covering the C-terminal region were expressed in E. coli cells harboring the plasmids; PCENPBO/2-16 (lane 1 in common), PCENPBO/1-1 (lane 2 in common) and PCENPBO/2-6(lane 3 in common). The reactivity of each CENPB product was tested with the sera of 40 patients, as described in the all the anticentromere sera. In contrast, the other three epitopes were not always recognized by all the patients. Oneserum that showedthe reactivity only to epitopes I and II was assigned to group 2. Fifteen sera showing reactivity to epitope IV were assigned to group 4. Another fifteen sera with the reactivity to epitope III, but not to epitope IV, were assigned to group 3. The antigenic determinant for epitope II had a unique feature, in that it could be recognized not only by the group 2 patient, but by the minority in groups 3 and 4 as well. These patients were assigned to subgroups 3b and 4b, respectively. Production ofanti-CENP-B serum with humanspecificity. Recently, a mouse homologue to human CENP-Bgene has been isolated and the human amino acid sequence for these epitopes could be compared with the mouse correspondences (25) . The amino acid sequences identical to those for epitopes III and IV have been found in mouse CENP-B (24) . As shown in Fig. 5 , the amino acid sequence for epitope I was also perfectly conserved in this species, suggesting that at least one of them might be the antigenic determinant commonto mammalian centromere proteins (4, 13, 16, 17, 20) . In contrast, epitope II shared less homology, indicating that it would actually be the one that defines a human specificity. To examine this possibility further, we attempted to produce an anti-CENP-B serum only specific to human centromere structure by immunizing mice with the recombinant human CENP-Bexpressed in E. coli. Although production-of polyclonal and monoclonal antibodies against human CENP-Bhas been reported, the species specificity was not the focus of inves- Whenwe tested mouse, monkey, bovine and porcine cell preparations, the same speckled staining patterns were obtained with the patient anticentromere autosera (panels B to E in Fig. 7 ). Although this patient serum contained other polyclonal antibodies against CENP-A and CENP-C as well, the same staining pattern was observed with other patient sera with relatively few anti-CENP-A or anti-CENP-C antibodies (18) (data not shown). Therefore, we assumedthat the antigenicity of the centromere proteins including CENP-Bwas preserved in these cell preparations.
We then examined whether the mouse anti-CENP-B serumwas reactive to other mammalian centromeres. However, no centromere staining pattern was observed in anybut human nuclei (panels ato ein Fig. 7 ). This result suggested the antigenic determinant recognized by this mouse serum should be specific to humancentro- mere and be different from that of other mammals. Epitope mapping of human-specific an tigenic determinant. To identify the antigenic determinant recognized by the mouse anti-CENP-B serum, we did the epitope mapping again. To estimate its location roughly, we used the previous set of truncated CENP-Bproducts which had been deleted from the C-terminus (24) . As shown in panel a in Fig. 8 , the C-terminal boundary was limited to position 492 using the pCENPBl-12 construct. This result suggested that the antigenic determinant was located within the C-terminal region encoded in the pCENPBl construct, since no antigenicity was detected in the upstream region. Wethen used the same set of CENP-Bproducts used for the analysis of epitopes I and II (see Fig. 1 ). The staining pattern was similar to that with the group 2 patient serum (panel b, Fig.   8 ). This result suggested that the antigenic determinant was within the 55 amino acid region encoded in the pCENPBl/1-12 construct, that was previously assigned to epitope II, corresponding to the only epitope with a less homologousamino acid sequence in mouse. To examine if it also reacted with epitope I, we tested the reactivity to the remaining set for epitope I. The expression of the recombinant products was confirmed by a rabbit serum raised against T7 phage gene 10 product (panel d, 
DISCUSSION
The four antigenic determinants on humanCENP-B have been characterized using anticentromere sera from autoimmune disease patients. Two of them have been located on the predicted helix-loop-helix structure of the N-terminal DNAbinding domain (24) . In this study, the remaining two were precisely located in separate regions on the C-terminus. The antigenic determinant for epitope I was limited to the 65 amino acid residues. We assumed it to be the "major epitope" on human CENP-B that was recognized by all the anticentromere sera from a variety of autoimmune disease patients (18, 19) , as described by Earnshaw et al. (8, 9) . In contrast, epitope II, limited to the 55 amino acid residues, was regarded as the so-called "minor epitope," which was Fig. 8 . Identification of the human-specific antigenic determinant defined by the mouse anti-CENP-B serum. a. The location of the antigenic determinant recognized by the mouse anti-CENP-B serum was roughly estimated using the previous set of truncated CENP-B products which had been deleted from the C-terminus, as described in the legends to Figs d. Epitope I was also recognized by the mouse anti-CENP-B serum. The CENP-B products were from the PCENPBO/2-16 (lanes 1 and 4), PCENPBO/1-1 (lanes 2 and 5) and PCENPBO/2-6 (lanes 3 and 6) constructs and the expression was confirmed by immunoblotting with the rabbit serum against T7 phage gene 10 product (lanes 1 to 3) . The reactivity of the mouse anti-CENP-B serum was tested (lanes 4 to 6).
only immunoreactive in a minority of patients. The requirement of relatively large regions for the antigenicity suggested that the secondary structure, rather than the primary structure, was recognized by the autoimmune sera.
Although "epitopes 1 to 3" have been predicted on the recombinant humanCENP-Bby a pioneer study of Earnshaw et al. (8, 9) , a detailed analysis has not been performed heretofore. Weassumed that epitope I corresponded to "epitope 1," since the antigenicity was destroyed by the dissection of the CENP-Bpolypeptide at the Ncol site (position 548) or by the 22-amino-acid deletion from the C-terminus (see PCENPB/NL and PCENPBO/1-1in Fig. 2, respectively) . Compared with the amino acid sequence of the previous humanCENP-B reported by Earnshaw et al. (8) , we found three substituted amino acids at positions 583 (Met), 592 (Leu) and 593 (Leu) in this region (Fig. 5) . The same substitutions have been predicted from the human genomic CENP-B sequence recently characterized by Sullivan and Glass (25) . Epitope II should correspond to "epitope 2," since it was located within the 104 amino acid stretch previously identified as epitope 2. "Epitope 3" would have been located on the N-terminal DNAbinding domain, since we could not detect any antigenicity in the region between 78 and 466 so far tested (data not shown). The patient sera have been grouped into 6 categories according to their reactivities to the four epitopes on human CENP-B (Fig. 4) . Each epitope seemed to be quite distinct: The patient sera from group 1 reacted with epitope I, but not with epitopes II, III or IV. Similarly, the group 2 patient serum did not react with epitopes III or IV. The group 3 patient sera did not recognize epitope IV. Moreover, epitope II was not always recognized by all the sera from groups 3 and 4. Although a minority of patient sera in groups 3b and 4b recognized epitope II, a monoclonal antibody which recognizes epitope II did not cross-react with the others (data not shown).
We have obtained the mouse anti-CENP-B serum which was only specific to human centromere (Fig. 7) . Centromereantigens with the molecular weight of 80 kDa have been detected in other mammalsusing anticentromere sera from autoimmune disease patients by several groups of investigators (2, 3). The homologous DNAsequences to human CENP-Bgene have been detected in other mammals and a chicken (data not shown) and the mouse CENP-Bgene has actually been isolated (25) . Therefore, we assumed that CENP-Bwas probably expressed among mammals.The epitope analysis of the mouse anti-CENP-B serum showed that the antigenic determinants were located at epitope II as well as epitope I. The amino acid sequence data of mouse CENP-Bmade it possible to predict that the difference within the 55 amino acid residues shown in Rabbit polyclonal antibodies to human CENP-B have been previously produced by Earnshaw et al. (8) .
Although the serum has been shownto recognize both epitopes 1 and 2 on human CENP-B, its failure "to stain somemammalian kinetochores or to recognize 80 kDa bands" in immunoblotting was also indicated in a recent review (unpublished observations in ref. 5). We do not know whyother mammaliancentromeres are unable to be stained by these sera raised against bacterially expressed human CENP-B. Mammalian CENP-B might interact with another molecule or have some protein modification at the epitope I region so that it would not react with anticentromere antibodies against epitopeI. Recently, we found that the bacterially expressed CENP-Bcould be phosphorylated in an in vitro reaction and that the phosphorylation site was at the putative casein kinase II site between positions 456 and 462 (Sugimoto and Himeno, Biosci. Biotech. Biochem. in press) . As in the case of epitopes III and IV (24), another important function of CENP-Bin vivo might be assigned to the epitope I and II regions. Knowledgeof the antiserum specific to humancentromere will allow us to focus on the behavior of a human CENP-Bwhen it is introduced into other mammalian cells, since it could not be distinguished from the host centromere proteins by the anticentromere autoimmune sera so far tested. It will enable us to analyze the expression and regulation profile of human CENP-Bgene in the future.
